PI3K/Akt/mTOR signalling pathway activation in patients with ER-positive, metachronous, contralateral breast cancer treated with hormone therapyHirofumi Kanaizumi(Kindai University), Y. Komoike(Kindai University)European Journal of CancerMarch 28, 201810.1016/s0959-8049(18)30502-1Cited by 13SaveCiteExport RISWatch citationsRelated PapersPI3K/Akt/mTOR signalling pathway activation in patients with ER‑positive, metachronous, contralateral breast cancer treated with hormone therapy|Oncology Letters|2018|16